miR-134-5p mimic

miR-134-5p mimic is a synthetic, double-stranded RNA oligonucleotide designed to mimic the activity of endogenous microRNA-134-5p (hsa-miR-134-5p). It is primarily utilized as an experimental research tool in transient gain-of-function studies to investigate miRNA-regulated gene expression, post-transcriptional control, and cellular phenotypes. Mechanistically, the mimic acts through the RNA interference (RNAi) pathway, binding to the 3'-untranslated region (3'-UTR) of target mRNAs to repress their translation or induce degradation. Key validated targets of miR-134-5p include ITGB1, MMP2, STAT5B, BDNF, CHST6, SFXN2, GRIK3, MBTD1, HSP90, BCL2, FOXM1, and KRAS. Preclinical academic studies have explored its therapeutic potential in various diseases, demonstrating that it can suppress malignant phenotypes (such as proliferation, migration, and invasion) in osteosarcoma, glioma, and triple-negative breast cancer, and reduce vascular remodeling in thoracic aortic dissection models, although it has been shown to promote cell migration in clear cell renal cell carcinoma. It is currently not in clinical development and has no commercial sponsor.

Other names

hsa-miR-134-5p mimichsa-miR134-5p mimichsa-miR 134-5p mimicmiR-134-5p-mimicmiR134-5p-mimicmiR 134-5p-mimic